Clinical trials: ALS (Amyotrophic Lateral Sclerosis)
Amyotrophic Lateral Sclerosis
Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis
Study the cervical spinal cord and brain over time to assess changes and differences in subjects with amyotrophic lateral sclerosis.
- Trial name
- NCT02058732
- Testing
- MRI
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan
Amyotrophic Lateral Sclerosis
To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers
Eligible subjects will receive either different dosages of HK-001 or placebo in a 3:1 ratio in 1 of the 7 dose cohorts. After single dose administration, followed by an independent Data and Safety Monitoring Board (DSMB) meeting…
- Trial name
- NCT03651349
- Testing
- HK-001
- Where
- Taiwan
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Everfront Biotech Co., Ltd.
Amyotrophic Lateral Sclerosis
Needs of ALS Patients With C9orf72 Mutation and Their Caregivers
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with…
- Trial name
- C9survALS (NCT07302321)
- Testing
- Survey for ALS patients, Survey for Caregivers
- Where
- 3 sites in Italy
- Volunteers
- 208 people
- Sponsor
- Istituto Auxologico Italiano
Tetraplegia/Tetraparesis, Quadriplegia
CAN-PRIME: Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
The CAN-PRIME Study is to test the safety and functionality of Neuralink's N1 Implant and R1 Robot in people who have difficulty moving their arms and legs (tetraparesis or tetraplegia).
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
- Trial name
- CAN-PRIME (NCT06700304)
- Testing
- N1 Implant, R1 Robot
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Neuralink Corp
Amyotrophic Lateral Sclerosis
Remote Speech and Swallowing Assessment in ALS
The investigators propose a longitudinal home study of ALS patients to measure the severity of speech and swallowing (bulbar) impairment via a smartphone-based, remote speech and swallow assessment (rSSA).
- Trial name
- NCT04889898
- Testing
- Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone, Modified Barium Swallow Study (MBSS), Speech Intelligibility Test (SIT)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Amyotrophic Lateral Sclerosis (ALS)
Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive diffuse muscular paralysis due to the inexorable loss of motor neurons in the primary motor cortex, the corticospinal tract, the…
- Trial name
- GOUSLA (NCT06608004)
- Testing
- test taking
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Amyotrophic Lateral Sclerosis (ALS)
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- MICABO-ALS (NCT04244630)
- Testing
- Antioxidants
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dallas VA Medical Center
ALS
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and tolerability of RNS60 in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02525471
- Testing
- RNS60
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sabrina Paganoni, M.D.
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis (ALS)
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
This is a multi-center, randomized, double blind, placebo controlled study to evaluate the safety and efficacy of autologous (self) transplantation of Neurotrophic factors-secreting Mesenchymal Stromal Cells (MSC-NTF, NurOwn™) in…
- Trial name
- NurOwn (NCT02017912)
- Testing
- Nurown MSC-NTF cells
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
Clinical Research in ALS Study
CRiALS is an umbrella protocol through which people are recruited to participate in a range of research studies being conducted by the ALS Research Collaboration (ARC).
- Trial name
- CRiALS (NCT00136500)
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Miami
ALS (Amyotrophic Lateral Sclerosis)
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which involves respiratory muscles and can lead at short term to respiratory failure.
- Trial name
- SLA (NCT02528071)
- Testing
- Diaphragmatic endurance test
- Where
- France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Biomarkers in Neurodegenerative Diseases
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD)
- Trial name
- NCT04055532
- Testing
- Neuraceq
- Where
- United States
- Sponsor
- University of Minnesota
Amyotrophic Lateral Sclerosis
A 6-Month Extension Study to Assess the Long-Term Safety of Engensis in Amyotrophic Lateral Sclerosis
The purpose of this study is to evaluate the long-term safety of intramuscular administration of Engensis in Participants with Amyotrophic Lateral Sclerosis who were previously randomized, received treatment, and completed the…
- Trial name
- REViVALS-1B (NCT05176093)
- Testing
- Engensis
- Where
- 2 sites in United States, South Korea
- Volunteers
- 8 people
- Sponsor
- Helixmith Co., Ltd.
Amyotrophic Lateral Sclerosis
Safety/Efficacy Study for the Treatment of Amyotrophic Lateral Sclerosis
A Phase I, single center, prospective, non-randomized, open label, safety/efficacy study of the infusion of autologous bone marrow-derived stem cells, in 6 patients with Amyotrophic Lateral Sclerosis according to established…
- Trial name
- ALS (NCT01082653)
- Testing
- autologous bone marrow-derived stem cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- TCA Cellular Therapy
ALS (Amyotrophic Lateral Sclerosis)
Virtual Reality for Anxiety Management in Persons With Amyotrophic Lateral Sclerosis
Virtual Reality (VR) is gaining traction as a new and innovative leisure to augment healthcare services. Several benefits of the leisure experience, such as distraction and full sensory immersion, have demonstrated a potential to…
- Trial name
- VR ALS (NCT07473765)
- Testing
- Virtual Reality Guided Breathing Exercise
- Volunteers
- 60 people
- Sponsor
- Horizon Health Network
Amyotrophic Lateral Sclerosis
Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis
To verify the correlation between TMAO level and the pathogenesis and progression of ALS
- Trial name
- NCT04948346
- Testing
- diagnosed with ALS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Frontotemporal Dementia (FTD), GRN Related Frontotemporal Dementia
Predict to Prevent PGRN Disease
Progranulin (GRN or PGRN) mutations are among the most common genetic causes of frontotemporal lobar degeneration (FTLD). With the advent of gene-specific therapeutic interventions, an accurate knowledge of the presymptomatic…
- Trial name
- PREVENT-PGRN (NCT06711510)
- Testing
- Clinical, behavioral and cognitive evaluation, blood sampling, brain MRI
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tetraplegia, Spinal Cord Injuries
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with…
- Conditions
- Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions
- Trial name
- BrainGate2 (NCT00912041)
- Testing
- Placement of the BrainGate2 sensor(s) into the motor-related cortex
- Where
- 6 sites in United States
- Volunteers
- 27 people
- Sponsor
- Leigh R. Hochberg, MD, PhD.
Amyotrophic Lateral Sclerosis
Contralateral R1 in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting both upper and lower motor neurons. Electroneuromyography is an important tool for the diagnosis.
- Trial name
- MOTOBLINK (NCT06206629)
- Testing
- blink reflex evaluation
- Where
- 2 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon